Dr. Michael D. Ehlers, Distinguished Neurobiologist, Joins Pfizer

Dr. Michael D. Ehlers, Distinguished Neurobiologist, Joins Pfizer

NEW YORK, N.Y., June 8, 2010 - Pfizer Inc. announced today that Michael D. Ehlers, M.D., Ph.D., has joined the company as Chief Scientific Officer for Neuroscience Research.  Dr. Ehlers brings significant scientific expertise and a history of results-oriented leadership to the company's premiere research organization.

Dr. Ehlers will report to Rod MacKenzie, Ph.D., Senior Vice President and Head of PharmaTherapeutics Research & Development.  
"I am thrilled that Mike Ehlers has chosen to join Pfizer and our outstanding research team," said Dr. MacKenzie.  "Mike is a world class scientist whose deep understanding of neurobiology will be a powerful asset as we build on the progress in our Neuroscience Research Unit and apply new thinking to deliver novel therapeutics in Alzheimer's disease, stroke, autism, and schizophrenia. His experience in the field and his passion for transforming medical outcomes are a winning combination in helping Pfizer create the industry's leading pipeline of neuroscience medicines."

Dr. Ehlers most recently served as the George Barth Geller Professor in the Department of Neurobiology at Duke University and as an investigator with the Howard Hughes Medical Institute.  Previously he served as the Director, Neuroproteomics Laboratory at Duke University.  He has authored over 60 scientific papers, and has been the recipient of numerous scientific awards, including the NARSAD Distinguished Investigator Award in 2009.

"I am excited to join an organization that has a clear and focused commitment to neuroscience research." said Dr. Ehlers.  "Having worked in this field for many years, I am impressed by the dedication of Pfizer scientists to finding treatments for devastating illnesses such as Alzheimer's disease, bipolar disorder and schizophrenia.  I look forward to bringing new insights and pushing forward these important areas of research in order to develop new medicines."


Media Contact:
Anne Wilson
(212) 733-5017

Investors Contact:
Suzanne Harnett
(212) 733-8009